Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 267989, 8 pages
http://dx.doi.org/10.1155/2015/267989
Research Article

Epitope Fingerprinting for Recognition of the Polyclonal Serum Autoantibodies of Alzheimer’s Disease

1Laboratório de Genética, Instituto de Genética e Bioquímica, Universidade Federal de Uberlândia, Rua Acre s/n, Bloco 2E sala 230, Campus Umuarama, 38400-902 Uberlândia, MG, Brazil
2Faculdade de Medicina, Universidade Federal de Uberlândia, Avenida Para 1720, Bloco 2U sala 23, Campus Umuarama, 38400-902 Uberlândia, MG, Brazil
3Laboratório de Nanobiotecnologia, Instituto de Genética e Bioquímica, Universidade Federal de Uberlândia, Rua Acre s/n, Bloco 2E sala 230, Campus Umuarama, 38400-902 Uberlândia, MG, Brazil

Received 28 June 2014; Accepted 18 February 2015

Academic Editor: Giovanni Scapagnini

Copyright © 2015 Luiz Carlos de Oliveira-Júnior et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Brunnström, L. Gustafson, U. Passant, and E. Englund, “Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports,” Archives of Gerontology and Geriatrics, vol. 49, no. 1, pp. 146–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. C. P. Ferri, M. Prince, C. Brayne et al., “Global prevalence of dementia: a Delphi consensus study,” The Lancet, vol. 366, no. 9503, pp. 2112–2117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. L. E. Hebert, P. A. Scherr, J. L. Bienias, D. A. Bennett, and D. A. Evans, “Alzheimer disease in the US population: prevalence estimates using the 2000 census,” Archives of Neurology, vol. 60, no. 8, pp. 1119–1122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. W. A. Rocca, A. Hofman, C. Brayne et al., “Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980–1990 prevalence findings,” Annals of Neurology, vol. 30, no. 3, pp. 381–390, 1991. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Olesen, A. Gustavsson, M. Svensson et al., “The economic cost of brain disorders in Europe,” European Journal of Neurology, vol. 19, no. 1, pp. 155–162, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Jönsson, M. E. Jönhagen, L. Kilander et al., “Determinants of costs of care for patients with Alzheimer's disease,” International Journal of Geriatric Psychiatry, vol. 21, no. 5, pp. 449–459, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. N. C. Fox and J. M. Schott, “Imaging cerebral atrophy: normal ageing to Alzheimer's disease,” The Lancet, vol. 363, no. 9406, pp. 392–394, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. R. S. Wilson, S. E. Leurgans, P. A. Boyle, and D. A. Bennett, “Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment,” Archives of Neurology, vol. 68, no. 3, pp. 351–356, 2011. View at Publisher · View at Google Scholar
  9. E. Braak, K. Griffing, K. Arai, J. Bohl, H. Bratzke, and H. Braak, “Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?” European Archives of Psychiatry and Clinical Neuroscience, vol. 249, no. 3, pp. S14–S22, 1999. View at Google Scholar · View at Scopus
  10. C. R. Jack Jr., R. C. Petersen, Y. Xu et al., “Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease,” Neurology, vol. 51, no. 4, pp. 993–999, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. D. J. Selkoe, “Alzheimer's disease: genes, proteins, and therapy,” Physiological Reviews, vol. 81, no. 2, pp. 741–766, 2001. View at Google Scholar · View at Scopus
  12. K. Gustaw-Rothenberg, A. Lerner, D. J. Bonda et al., “Biomarkers in Alzheimers disease: past, present and future,” Biomarkers in Medicine, vol. 4, no. 1, pp. 15–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Bouras, B. M. Riederer, E. Kövari, P. R. Hof, and P. Giannakopoulos, “Humoral immunity in brain aging and Alzheimer's disease,” Brain Research Reviews, vol. 48, no. 3, pp. 477–487, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. J. Khandelwal, A. M. Herman, and C. E.-H. Moussa, “Inflammation in the early stages of neurodegenerative pathology,” Journal of Neuroimmunology, vol. 238, no. 1-2, pp. 1–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Diamond, P. T. Huerta, P. Mina-Osorio, C. Kowal, and B. T. Volpe, “Losing your nerves? Maybe it's the antibodies,” Nature Reviews Immunology, vol. 9, no. 6, pp. 449–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Maetzler, D. Berg, M. Synofzik et al., “Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of lewy body-associated dementias,” Journal of Alzheimer's Disease, vol. 26, no. 1, pp. 171–179, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Daniilidou, M. Tsolaki, T. Giannakouros, and E. Nikolakaki, “Detection of elevated antibodies against SR protein kinase 1 in the serum of Alzheimer's disease patients,” Journal of Neuroimmunology, vol. 238, no. 1-2, pp. 67–72, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. T. V. Davydova, N. I. Voskresenskaya, V. Y. Gorbatov, V. G. Fomina, O. A. Doronina, and I. V. Maksunova, “Production of autoantibodies to glutamate during Alzheimer's dementia,” Bulletin of Experimental Biology and Medicine, vol. 147, no. 4, pp. 405–407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. E. C. Levin, N. K. Acharya, M. Han et al., “Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown,” Brain Research, vol. 1345, pp. 221–232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Vacirca, C. Barbati, B. Scazzocchio et al., “Anti-ATP synthase autoantibodies from patients with Alzheimer's disease reduce extracellular HDL level,” Journal of Alzheimer's Disease, vol. 26, no. 3, pp. 441–445, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Colasanti, C. Barbati, G. Rosano, W. Malorni, and E. Ortona, “Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression,” Autoimmunity Reviews, vol. 9, no. 12, pp. 807–811, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Neff, X. Wei, C. Nölker, M. Bacher, Y. Du, and R. Dodel, “Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders,” Autoimmunity Reviews, vol. 7, no. 6, pp. 501–507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Paul, S. Planque, and Y. Nishiyama, “Immunological origin and functional properties of catalytic autoantibodies to amyloid β peptide,” The Journal of Clinical Immunology, vol. 30, supplement 1, pp. S43–S49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. H. R. Hoogenboom, A. P. de Brune, S. E. Hufton, R. M. Hoet, J.-W. Arends, and R. C. Roovers, “Antibody phage display technology and its applications,” Immunotechnology, vol. 4, no. 1, pp. 1–20, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Rader and C. F. Barbas, “Phage display of combinatorial antibody libraries,” Current Opinion in Biotechnology, vol. 8, no. 4, pp. 503–508, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. U. Kriplani and B. K. Kay, “Selecting peptides for use in nanoscale materials using phage-displayed combinatorial peptide libraries,” Current Opinion in Biotechnology, vol. 16, no. 4, pp. 470–475, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. S. F. Altschul, T. L. Madden, A. A. Schäffer et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research, vol. 25, no. 17, pp. 3389–3402, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Huang, B. Ru, and P. Dai, “Bioinformatics resources and tools for phage display,” Molecules, vol. 16, no. 1, pp. 694–709, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Mayrose, T. Shlomi, N. D. Rubinstein et al., “Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm,” Nucleic Acids Research, vol. 35, no. 1, pp. 69–78, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, text revision, American Psychiatric Association, Washington, DC, USA, 4th edition, 2000.
  31. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E. M. Stadlan, “Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease,” Neurology, vol. 34, no. 7, pp. 939–944, 1984. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Montaño and L. R. Ramos, “Validade da versão em português da clinical dementia rating,” Revista de Saúde Pública, vol. 39, no. 6, pp. 912–917, 2005. View at Publisher · View at Google Scholar
  33. M. F. Folstein, S. E. Folstein, and P. R. McHugh, “‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician,” Journal of Psychiatric Research, vol. 12, no. 3, pp. 189–198, 1975. View at Google Scholar
  34. C. F. Reis, A. P. Carneiro, C. U. Vieira et al., “An antibody-like peptide that recognizes malignancy among thyroid nodules,” Cancer Letters, vol. 335, no. 2, pp. 306–313, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. J. E. Larsen, O. Lund, and M. Nielsen, “Improved method for predicting linear B-cell epitopes,” Immunome Research, vol. 2, article 2, 2006. View at Publisher · View at Google Scholar
  36. H. R. Ansari and G. P. Raghava, “Identification of conformational B-cell Epitopes in an antigen from its primary sequence,” Immunome Research, vol. 6, no. 1, article 6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. M. A. Arap, “Phage display technology—applications and innovations,” Genetics and Molecular Biology, vol. 28, no. 1, pp. 1–9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. O. H. Aina, R. Liu, J. L. Sutcliffe, J. Marik, C.-X. Pan, and K. S. Lam, “From combinatorial chemistry to cancer-targeting peptides,” Molecular Pharmaceutics, vol. 4, no. 5, pp. 631–651, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Vodnik, U. Zager, B. Strukelj, and M. Lunder, “Phage display: selecting straws instead of a needle from a haystack,” Molecules, vol. 16, no. 1, pp. 790–817, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. N. Manhani, V. S. Ribeiro, R. Cardoso, C. Ueira-Vieira, L. R. Goulart, and J. M. Costa-Cruz, “Specific phage-displayed peptides discriminate different forms of neurocysticercosis by antibody detection in the serum samples,” Parasite Immunology, vol. 33, no. 6, pp. 322–329, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. V. da Silva Ribeiro, M. N. Manhani, R. Cardoso, C. U. Vieira, L. R. Goulart, and J. M. Costa-Cruz, “Selection of high affinity peptide ligands for detection of circulating antibodies in neurocysticercosis,” Immunology Letters, vol. 129, no. 2, pp. 94–99, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. L. R. Goulart, C. U. Vieira, A. P. P. Freschi et al., “Biomarkers for serum diagnosis of infectious diseases and their potential application in novel sensor platforms,” Critical Reviews in Immunology, vol. 30, no. 2, pp. 201–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. B.-X. Qu, Y. Gong, C. Moore et al., “Beta-amyloid auto-antibodies are reduced in Alzheimer’s disease,” Journal of Neuroimmunology, vol. 274, no. 1-2, pp. 168–173, 2014. View at Publisher · View at Google Scholar
  44. Y. Du, X. Wei, R. Dodel et al., “Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity,” Brain, vol. 126, no. 9, pp. 1935–1939, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. X.-P. Wang, J.-H. Zhang, Y.-J. Wang et al., “Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers,” FEBS Letters, vol. 583, no. 3, pp. 579–584, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. J. L. Richens, K. Morgan, and P. O'Shea, “Reverse engineering of Alzheimer's disease based on biomarker pathways analysis,” Neurobiology of Aging, vol. 35, no. 9, pp. 2029–2038, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Ray and W. Zhang, “Analysis of Alzheimer's disease severity across brain regions by topological analysis of gene co-expression networks,” BMC Systems Biology, vol. 4, no. 1, article 136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Drees and F. B. Gertler, “Ena/VASP: proteins at the tip of the nervous system,” Current Opinion in Neurobiology, vol. 18, no. 1, pp. 53–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Urbanelli, C. Massini, C. Emiliani, A. Orlacchio, and G. Bernardi, “Characterization of human Enah gene,” Biochimica et Biophysica Acta—Gene Structure and Expression, vol. 1759, no. 1-2, pp. 99–107, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. D. L. Franco, C. Rezával, A. Cáceres, A. F. Schinder, and M. F. Ceriani, “ENA/VASP downregulation triggers cell death by impairing axonal maintenance in hippocampal neurons,” Molecular and Cellular Neuroscience, vol. 44, no. 2, pp. 154–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Trillo, D. Das, W. Hsieh et al., “Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care,” Neuroscience and Biobehavioral Reviews, vol. 37, no. 8, pp. 1363–1379, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. P. R. Pennington, Z. Wei, L. Rui et al., “Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro,” Journal of Neural Transmission, vol. 118, no. 7, pp. 987–995, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Rogelj, J. C. Mitchell, C. C. J. Miller, and D. M. McLoughlin, “The X11/Mint family of adaptor proteins,” Brain Research Reviews, vol. 52, no. 2, pp. 305–315, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Chaufty, S. E. Sullivan, and A. Ho, “Intracellular amyloid precursor protein sorting and amyloid-β secretion are regulated by Src-mediated phosphorylation of Mint2,” Journal of Neuroscience, vol. 32, no. 28, pp. 9613–9625, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. M. F. Matos, Y. Xu, I. Dulubova et al., “Autoinhibition of Mint1 adaptor protein regulates amyloid precursor protein binding and processing,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 10, pp. 3802–3807, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. J.-H. Lee, K.-F. Lau, M. S. Perkinton et al., “The Neuronal Adaptor Protein X11α Reduces Aβ Levels in the Brains of Alzheimer's APPswe Tg2576 Transgenic Mice,” The Journal of Biological Chemistry, vol. 278, no. 47, pp. 47025–47029, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. F. Maina and R. Klein, “Hepatocyte growth factor, a versatile signal for developing neurons,” Nature Neuroscience, vol. 2, no. 3, pp. 213–217, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Tsuboi, K. Kakimoto, M. Nakajima et al., “Increased hepatocyte growth factor level in cerebrospinal fluid in Alzheimer's disease,” Acta Neurologica Scandinavica, vol. 107, no. 2, pp. 81–86, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Fenton, P. W. Finch, J. S. Rubin et al., “Hepatocyte growth factor (HGF/SF) in Alzheimer's disease,” Brain Research, vol. 779, no. 1-2, pp. 262–270, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. P. J. Cullen, “Endosomal sorting and signalling: an emerging role for sorting nexins,” Nature Reviews Molecular Cell Biology, vol. 9, no. 7, pp. 574–582, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. H.-S. Huang, B.-J. Yoon, S. Brooks et al., “Snx14 regulates neuronal excitability, promotes synaptic transmission, and is imprinted in the brain of mice,” PLoS ONE, vol. 9, no. 5, Article ID e98383, 2014. View at Publisher · View at Google Scholar
  62. R. Mizutani, K. Nakamura, N. Kato et al., “Expression of sorting nexin 12 is regulated in developing cerebral cortical neurons,” Journal of Neuroscience Research, vol. 90, no. 4, pp. 721–731, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Zhao, Y. Wang, J. Yang, X. Wang, X. Zhang, and Y.-W. Zhang, “Sorting nexin 12 interacts with BACE1 and regulates BACE1-mediated APP processing,” Molecular Neurodegeneration, vol. 7, no. 1, article 30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. X. Wang, Y. Zhao, X. Zhang et al., “Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction by modulating glutamate receptor recycling in Down's syndrome,” Nature Medicine, vol. 19, no. 4, pp. 473–480, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. B. Li, D. Yu, and Z. Xu, “Activated protein C inhibits amyloid β production via promoting expression of ADAM-10,” Brain Research, vol. 1545, pp. 35–44, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Guo, D. Liu, H. Gelbard et al., “Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3,” Neuron, vol. 41, no. 4, pp. 563–572, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Oku and R. L. Huganir, “AGAP3 and Arf6 regulate trafficking of AMPA receptors and synaptic plasticity,” Journal of Neuroscience, vol. 33, no. 31, pp. 12586–12598, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Nagashima, T. Fukuda, Y. Kubota et al., “CRMP5-associated GTPase (CRAG) protein protects neuronal cells against cytotoxicity of expanded polyglutamine protein partially via c-fos-dependent activator protein-1 activation,” The Journal of Biological Chemistry, vol. 286, no. 39, pp. 33879–33889, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. E. Nagele, M. Han, C. DeMarshall, B. Belinka, and R. Nagele, “Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera,” PLoS ONE, vol. 6, no. 8, Article ID e23112, 2011. View at Publisher · View at Google Scholar · View at Scopus